Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 101–200 of 1,000
Couturaud, F., Schmidt, J., Sanchez, O., Ballerie, A., Sevestre, M., Meneveau, N. F., Bertoletti, L., Connault, J., Benhamou, Y., Constans, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02842-3 · Cited by 118
“18 However, with the inclusion of a placebo 17 or aspirin 18 control group, both studies enrolled patients in whom physicians were uncertain about continuing anticoagulation, and neither was designed or powered to compare reduced-dose with full-dose anticoagulation in terms of efficacy and safety.”
InfluentialLevy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Steiner, T., Weitz, J. I., & Veltkamp, R. C. (2017) · Stroke · doi:10.1161/strokeaha.116.013343 · Cited by 116
Self-citationThe New Oral Anticoagulants in Clinical Practice
Gonsalves, W. I., Pruthi, R. K., & Patnaik, M. M. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.03.006 · Cited by 112
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Caldeira, D., Barra, M., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7462-0 · Cited by 111
“NOACs were compared against placebo in one extended study period of an apixaban RCT in patients with post-VTE [24], and in two RCTs with ACS patients [20, 34].”
MethodWoller, S. C., Stevens, S. M., Kaplan, D. A., Branch, D. W., Aston, V. T., Wilson, E. L., Gallo, H. M., Johnson, E., Rondina, M. T., Lloyd, J. F., et al. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615615960 · Cited by 106
“5 mg twice a day with placebo for the prevention of recurrent venous thrombosis.(11) Apixaban for Extended Treatment of Venous Thromboembolism (AMPLIFY-EXT) was designed to determine whether apixaban 2.”
BackgroundThe evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed Central · doi:10.2450/2015.0096-15 · Cited by 127
Alexander, J. H., Andersson, U., Lopes, R. D., Hijazi, Z., Hohnloser, S. H., Ezekowitz, J. A., Halvorsen, S., Hanna, M., Commerford, P., Ruzyllo, W., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1829 · Cited by 96
Acute pulmonary embolism: a concise review of diagnosis and management
Rayner, M., Darvall, J. N., & Hammerschlag, G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14145 · Cited by 120
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Brandão, L. R., Albisetti, M., Halton, J., Bomgaars, L. R., Chalmers, E. A., Mitchell, L. G., Nurmeev, I. N., Svirin, P., Kuhn, T., Zapletal, O., et al. (2019) · Blood · doi:10.1182/blood.2019000998 · Cited by 105
Bleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 105
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)
Hepatobiliary Disease Study Group, C. S. O. G. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12970 · Cited by 106
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001415 · Cited by 256
Eichinger, S., Heinze, G., & Kyrle, P. A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000467 · Cited by 99
Baugh, C. W., Levine, M. P., Cornutt, D., Wilson, J. W., Kwun, R., Mahan, C. E., Pollack, C. V., Marcolini, E. G., Milling, T. J., Peacock, W. F., et al. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.09.001 · Cited by 101
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 111
“In a meta-analysis (20) of four studies (17, 21, 22) in the extended therapy of VTE comprising 7892 randomized patients, the DOAC were more effective than placebo in preventing recurrent VTE (RR: 0.”
BackgroundKlemen, N. D., Feingold, P. L., Hashimoto, B., Wang, M., Kleyman, S., Brackett, A. L., Gross, C. P., & Pei, K. Y. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30211-8 · Cited by 100
Venous thromboembolism: Recent advancement and future perspective
Yamashita, Y., Morimoto, T., & Kimura, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.08.026 · Cited by 106
Noble, S., Nelson, A., & Seaman, S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58595 · Cited by 91
Gianesini, S., Obi, A. T., Onida, S., Baccellieri, D., Bissacco, D., Борсук, Д. А., Campisi, C., Campisi, C. C., Cavezzi, A., Chi, Y., et al. (2019) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355519870690 · Cited by 99
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 93
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Self-citationUpdate on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 91
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 93
External validation of the DASH prediction rule: a retrospective cohort study
Tosetto, A., Testa, S., Martinelli, I., Poli, D., Cosmi, B., Lodigiani, C., Ageno, W., Stefano, V. D., Falanga, A., Nichele, I., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13781 · Cited by 90
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 87
Robertson, L., Kesteven, P., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub2 · Cited by 78
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.008 · Cited by 94
Dammacco, F., Vacca, A., Procaccio, P., Ria, R., Marech, I., & Racanelli, V. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-013-0230-0 · Cited by 84
“In patients for whom there is clinical equipoise as to whether anticoagulation therapy should be continued or interrupted, extended anticoagulation with apixaban has been shown to reduce the risk of recurrent VTE without inducing a higher rate of major bleeding [55].”
BackgroundCohen, H., Doré, C. J., Clawson, S., Hunt, B. J., Isenberg, D., Khamashta, M. A., & Muirhead, N. (2015) · Lupus · doi:10.1177/0961203315581207 · Cited by 81
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 82
“Dabigatran, rivaroxaban, and 2 doses of apixaban were compared with placebo in patients with uncertainty about the clinical benefit of continued anticoagulation (39,86,87).”
Self-citationSafety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
Venous Thromboembolism in Gynecological Malignancy
Cohen, A., Lim, C. S., & Davies, A. H. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001111 · Cited by 77
Self-citationPopulation Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
Cirincione, B. B., Kowalski, K. G., Nielsen, J. C., Roy, A., Thanneer, N., Byon, W., Boyd, R. A., Wang, X., Leil, T. A., LaCreta, F. P., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12347 · Cited by 81
Cheung, Y. W., Barco, S., Hutten, B. A., Meijers, J. C. M., Middeldorp, S., & Coppens, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13115 · Cited by 73
Coons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Sardar, P., Chatterjee, S., Herzog, E., Nairooz, R. S., Mukherjee, D., & Halperin, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.015 · Cited by 70
New oral anticoagulants in elderly patients
Barco, S., Cheung, Y. W., Eikelboom, J. W., & Coppens, M. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.011 · Cited by 70
Alotaibi, G., Almodaimegh, H., McMurtry, M. S., & Wu, C. M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.07.017 · Cited by 71
“AMPLIFY -EXT, 2012 [21] 2486 Apixaban Placebo 12 months VTE 56.”
BackgroundByon, W., Sweeney, K., Frost, C., & Boyd, R. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12184 · Cited by 79
“The population pharmacokinetic and pharmacokinetic– pharmacodynamic analyses utilized intensive and sparse data collected in eight phase I studies, one phase II DVT study,(22) and two phase III VTE treatment clinical trials (Table 1).(1,2) Two blood samples at steady state (Weeks 3 and 12) were collected for measureme…”
BackgroundMethodInfluentialLong-term mortality after massive, submassive, and low-risk pulmonary embolism
Gupta, R., Ammari, Z. A., Dasa, O., Ruzieh, M., Burlen, J., Shunnar, K. M., Nguyen, H. T., Xie, Y., Brewster, P. S., Chen, T., et al. (2019) · Vascular Medicine · doi:10.1177/1358863x19886374 · Cited by 73
Ezekowitz, J. A., Lewis, B. S., Lópes, R. D., WOJDYLA, D. M., McMurray, J. J. V., Hanna, M., Atar, D., Bahit, M. C., Keltai, M., Lopez-Sendon, J. L., et al. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu024 · Cited by 69
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 73
Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)
Nakamura, M., Nishikawa, M., Komuro, I., Kitajima, I., Uetsuka, Y., Yamagami, T., Minamiguchi, H., Yoshimatsu, R., Tanabe, K., Matsuoka, N., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0195 · Cited by 67
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., Palareti, G., & START-Register (2015) · PLoS ONE · doi:10.1371/journal.pone.0124719 · Cited by 71
“Several phase III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6], and studies of acute[7–11]or extended [12,13] treatment in patients with venous thromboembolism (VTE) have recently been published investigating the efficacy and safety of 4 different DOAC (dabigatran, rivar…”
BackgroundGorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · EP Europace · doi:10.1093/europace/euac020 · Cited by 75
Caldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., GROSSO, M. A., Segers, A. E. M., Meyer, G., Verhamme, P. B., Wells, P. S., Lin, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00023-5 · Cited by 68
Self-citationPractical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
“Low rates of bleeding were also seen in the extended treatment studies where, compared with placebo, dabigatran, rivaroxaban and apixaban reduced the risk of recurrent VTE by 80–92 % without any significant increase in major bleeding (▶ Table 2) (22, 24, 25).”
ResultSelf-citationNew oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 69
“In three placebo-controlled trials the new anticoagulants always gave a substantial reduction of risk for recurrence without a significant increase of major bleeding (16, 19, 26).”
BackgroundSwan, D., Rocci, A., Bradbury, C. A., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15684 · Cited by 68
Risk of venous thromboembolism in rheumatoid arthritis
Ketfi, C., Boutigny, A., Mohamedi, N., Bouajil, S., Magnan, B., Amah, G., & Dillinger, J. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.105122 · Cited by 70
COVID-19 and Its Implications for Thrombosis and Anticoagulation
Berkman, S. A., & Tapson, V. F. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1722992 · Cited by 65
Cohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
“Prior treatment duration of studies included in the NMA varied from a minimum of 3 months in the LAFIT [35], ELATE [36], WODIT DVT [37], WODIT PE [32], RE-MEDY [18] and PREVENT [38] trials, up to 6–18 months in the AMPLIFY- EXT [17], EINSTEIN-EXT [19], WARFASA [33] and RE-SONATE [18] trials and 24 months in the ASPIRE…”
BackgroundMethodInfluentialSelf-citationMoik, F., Colling, M. E., Mahé, I., Jara‐Palomares, L., Pabinger, I., & Ay, C. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15599 · Cited by 63
Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline
Liu, D. M., Peterson, E. A., Dooner, J., Baerlocher, M. O., Zypchen, L. N., Gagnon, J., Delorme, M., Sing, C. K., Wong, J., Guzman, R., et al. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141614 · Cited by 68
Beyer‐Westendorf, J., Michalski, F., Tittl, L., Hauswald-Dörschel, S., & Marten, S. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30111-9 · Cited by 61
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis
Wang, K.-L., van Es, N., Cameron, C. G., Castellucci, L. A., Buller, H. R., & Carrier, M. (2018) · Heart · doi:10.1136/heartjnl-2018-313617 · Cited by 64
Self-citationHow I treat patients with hereditary antithrombin deficiency
Pabinger, I., & Thaler, J. (2019) · Blood · doi:10.1182/blood.2019002927 · Cited by 65
Arachchillage, D. J., Mackie, I. J., Efthymiou, M., Isenberg, D. A., Machin, S. J., & Cohen, H. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12917 · Cited by 61
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
Camire, R. M. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02456-w · Cited by 59
Statins Effects on Blood Clotting: A Review
Siniscalchi, C., Basaglia, M., Riva, M. A., Meschi, M., Meschi, T., Castaldo, G., & Micco, P. D. (2023) · Cells · doi:10.3390/cells12232719 · Cited by 62
“Low molecular weight heparin (LMWH), unfractionated heparin (UFH), vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are the gold standard of treatment for VTE [3,4], despite their related risk of bleeding [3,4].”
BackgroundMcBane, R. D., Loprinzi, C. L., Zemla, T., Tafur, A. J., Sanfilippo, K. M., Liu, J. J., Garcia, D. A., Heun, J. M., Gundabolu, K., Onitilo, A. A., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.011 · Cited by 59
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Frost, C. E., Shenker, A., Gandhi, M. D., Pursley, J. M., Barrett, Y. C., Wang, J. J. J., Zhang, D., Byon, W., Boyd, R. A., & LaCreta, F. P. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12393 · Cited by 63
Mahé, I., Agnelli, G., Ay, C., Bamias, A., Becattini, C., Carrier, M., Chapelle, C., Cohen, A. T., Girard, P., Huisman, M. V., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1647-9896 · Cited by 62
Self-citationGómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
Safety of direct oral anticoagulants in patients with advanced liver disease
Semmler, G., Pomej, K., Bauer, D. J. M., Balcar, L., Simbrunner, B., Binter, T., Hartl, L., Becker, J., Pinter, M., Quehenberger, P., et al. (2021) · Liver International · doi:10.1111/liv.14992 · Cited by 57
Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease
Payne, R. M., Burns, K. M., Glatz, A. C., Male, C., Donti, A., Brandão, L. R., Balling, G., VanderPluym, C. J., Bu'Lock, F. A., Kochilas, L. K., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.010 · Cited by 67
Loke, Y. K., Pradhan, S., Yeong, J. K.-Y., & Kwok, C. S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12376 · Cited by 63
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 61
“Most recently, it has been approved for the treatment of DVT and PE and the reduction in the risk of recurrent DVT and PE following initial therapy [38, 39].”
BackgroundChatterjee, S., Sardar, P., Giri, J. S., Ghosh, J., & Mukherjee, D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.030 · Cited by 59
O’Brien, S. H., Rodriguez, V., Lew, G., Newburger, J. W., Schultz, C. L., Orgel, E., Derr, K., Ranalli, M. A., Esbenshade, A. J., Hochberg, J. C., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00314-9 · Cited by 56
Áinle, F. N., & Kevane, B. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002268 · Cited by 67
“Cosmi et al 2010 (52) Prospective multicenter study (first unprovoked VTE) N/R D-dimer 1 mo after D/C AC Persistently abnormal D-dimer: 27%/person-years (12-48)”
BackgroundTreatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Carrier, M., Blais, N., Crowther, M. A., Kavan, P., Gal, G. L., Moodley, O., Shivakumar, S., Suryanarayan, D., Tagalakis, V., Wu, C. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060453 · Cited by 62
“Several studies have also investigated the safety and efficacy of prophylactic doses of DOACs for the extended treatment of VTE [78,79].”
BackgroundAntithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 59
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub2 · Cited by 62
How I treat heavy menstrual bleeding associated with anticoagulants
Boonyawat, K., O’Brien, S. H., & Bates, S. M. (2017) · Blood · doi:10.1182/blood-2017-07-797423 · Cited by 62
“The effectiveness of a lower-dose DOAC for prevention of recurrent thrombosis in patients who have received at least 6 months of therapy has been demonstrated with apixaban and rivaroxaban.(64,65) One observational study reported successful HMBmanagement by switching from rivaroxaban to apixaban in 5 (70%) of 7 women.”
BackgroundCerebral Venous Thrombosis: We Should Ask the Right Questions to Get Better Answers
Field, T. S., & Hill, M. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025334 · Cited by 57
Marik, P. E., & Cavallazzi, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143252 · Cited by 53
“5 mg and 5 mg dosages, [30] for the purposes of this meta-analysis we combined the data of the two dosage arms.”
BackgroundMethodApixaban for Extended Treatment of Provoked Venous Thromboembolism
Piazza, G., Bikdeli, B., Pandey, A. K., Krishnathasan, D., Khairani, C. D., Bejjani, A., Morrison, R. H., Hogan, H., Rashedi, S., Pfeferman, M. B., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2509426 · Cited by 65
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors
Liu, M., Zaman, K., & Fortenberry, Y. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083897 · Cited by 54
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 65
Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Brighton, T., Cohen, A. T., Davidson, B. L., Holberg, G., Kakkar, A. K., Lensing, A. W. A., Prins, M. H., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0131 · Cited by 55
“Although both regimens were associated with low rates of major bleeding, the rate of clinically relevant nonmajor bleeding was higher with the 5 mg apixaban regimen (11).”
BackgroundSelf-citationWeinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 56
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Self-citationEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Self-citationUse of New Oral Anticoagulants in Antiphospholipid Syndrome
Arachchillage, D. J., & Cohen, H. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0331-5 · Cited by 55
Aspirin for prevention and treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.003 · Cited by 53
“5 mg or 5 mg twice daily) or placebo in a double blind fashion [55].”
BackgroundSelf-citationThe role of factor Xa inhibitors in venous thromboembolism treatment
Cabral, K. P., & Ansell, J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39726 · Cited by 50
“Similar to rivaroxaban, apixaban was also studied as extended treatment of VTE in the AMPLIFY-EXT trial.(21) This randomized, double-blind study compared apixaban 5 mg BID, 2.”
Harder, S. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-22 · Cited by 54
Sardar, P., Chatterjee, S., & Mukherjee, D. (2013) · Drugs · doi:10.1007/s40265-013-0082-7 · Cited by 50
“Of the identified trials, two trials evaluated dabigatran [11] and one trial each evaluated rivaroxaban [10] and apixaban [9].”
BackgroundPalareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., Testa, S., Tosetto, A., & Prandoni, P. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14253 · Cited by 52
2020 Clinical practice guidelines for Myocarditis in adults
Arutyunov, G. P., Палеев, Ф. Н., Моисеева, О. М., Драгунов, Д. О., Sokolova, A. V., Arutyunov, A. G., Жиров, И. В., Blagova, O. V., Privalova, E. V., Габрусенко, С. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4790 · Cited by 56
Management of venous thromboembolism: an update
Piran, S., & Schulman, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0107-z · Cited by 53
“All trials showed marked superiority of the DOACs over placebo for the prevention of recurrent VTE without significant increase in major bleeding [17,50, 51].”
BackgroundMethodResultInfluentialIncidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma
Wendelboe, A. M., Campbell, J. E., Ding, K., Bratzler, D. W., Beckman, M. G., Reyes, N., & Raskob, G. E. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1722189 · Cited by 50
Self-citationLiew, A., Eikelboom, J. W., O'Donnell, M. J., & Hart, R. G. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.013 · Cited by 58
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.